Previous studies by our group have demonstrated a marked decrease in gene-expression levels of both these NF-kB inhibitors in whole blood and peripheral blood mononuclear cells (PBMCs) of MS patients compared with healthy controls (HCs) (16–19). This evidence concerns the gene NFKB1 and myeloid sarcoma.